Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
analogues of penicillanic acid antibiotics modified in the five-membered ring	1426	64221-86-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: imipenem tienamycin imipemide imipenen imipenem hydrate	Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor. Molecular weight: 299.35 Formula: C12H17N3O4S CLOGP: -0.39 LIPINSKI: 0 HAC: 7 HDO: 4 TPSA: 113.72 ALOGS: -2.64 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

imipenem
tienamycin
imipemide
imipenen
imipenem hydrate

Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.

Molecular weight: 299.35
Formula: C12H17N3O4S
CLOGP: -0.39
LIPINSKI: 0
HAC: 7
HDO: 4
TPSA: 113.72
ALOGS: -2.64
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	P
2	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	69 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	222.82 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	1 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.24 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.86 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.95 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHUK,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PIK3CA,PIK3CB,PIM2,PLK1,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK	49
kinase-selectivity-class	AXL,BRAF,CDK9,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,TEK,TGFBR1	13
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company
June 23, 2021	PMDA	MSD K.K.
Feb. 13, 2020	EMA	Merck Sharp & Dohme B.V.
Nov. 26, 1985	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug resistance	165.34	24.95	64	5412	30385	90592586
Seizure	124.86	24.95	90	5386	152539	90470432
Pathogen resistance	106.49	24.95	33	5443	8082	90614889
Multiple organ dysfunction syndrome	104.99	24.95	60	5416	68276	90554695
Septic shock	88.52	24.95	58	5418	84102	90538869
Clostridium difficile colitis	65.29	24.95	32	5444	26674	90596297
Ototoxicity	62.61	24.95	16	5460	1948	90621023
Renal failure	57.80	24.95	54	5422	130953	90492018
Geotrichum infection	57.36	24.95	12	5464	604	90622367
Sepsis	57.08	24.95	62	5414	179752	90443219
Hepatic infarction	56.07	24.95	12	5464	674	90622297
Aspergillus infection	56.04	24.95	22	5454	10801	90612170
Mycobacterium abscessus infection	55.97	24.95	13	5463	1062	90621909
Drug ineffective	53.99	24.95	194	5282	1384104	89238867
Respiratory failure	50.67	24.95	48	5428	118370	90504601
Acute kidney injury	47.59	24.95	76	5400	320311	90302660
Aplasia	47.22	24.95	15	5461	3976	90618995
Deafness	40.63	24.95	22	5454	22492	90600479
Electrocardiogram QT prolonged	40.15	24.95	34	5442	72422	90550549
Rash maculo-papular	40.07	24.95	27	5449	40906	90582065
Hepatotoxicity	39.60	24.95	28	5448	45814	90577157
Eosinophilic pneumonia acute	39.10	24.95	9	5467	706	90622265
Thrombocytopenia	37.30	24.95	54	5422	208671	90414300
Bone marrow failure	35.78	24.95	23	5453	32198	90590773
Drug reaction with eosinophilia and systemic symptoms	34.37	24.95	25	5451	42733	90580238
Pain	34.34	24.95	9	5467	996332	89626639
Enterococcal infection	33.81	24.95	15	5461	9976	90612995
Haemophagocytic lymphohistiocytosis	33.28	24.95	17	5459	15442	90607529
Candida infection	32.22	24.95	22	5454	34035	90588936
Heparin-induced thrombocytopenia	31.79	24.95	12	5464	5300	90617671
Granulomatosis with polyangiitis	31.76	24.95	10	5466	2575	90620396
Toxic epidermal necrolysis	30.74	24.95	21	5455	32507	90590464
Drug level below therapeutic	30.74	24.95	12	5464	5802	90617169
Pyrexia	30.26	24.95	98	5378	660387	89962584
Generalised tonic-clonic seizure	29.41	24.95	21	5455	34882	90588089
Pancytopenia	28.95	24.95	36	5440	120227	90502744
Bronchopulmonary aspergillosis	28.87	24.95	14	5462	11384	90611587
Eosinophilia	28.35	24.95	19	5457	28514	90594457
Type IV hypersensitivity reaction	27.66	24.95	10	5466	3916	90619055
Systemic candida	25.39	24.95	10	5466	4949	90618022
Fungaemia	25.36	24.95	9	5467	3341	90619630
Tooth discolouration	25.08	24.95	7	5469	1191	90621780

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	156.23	20.74	362	7925	629835	41983213
Drug resistance	154.05	20.74	91	8196	34157	42578891
Multiple organ dysfunction syndrome	127.12	20.74	123	8164	96912	42516136
Pathogen resistance	127.00	20.74	56	8231	11394	42601654
Septic shock	117.80	20.74	115	8172	91557	42521491
Ototoxicity	104.82	20.74	32	8255	2293	42610755
Eosinophilia	99.36	20.74	68	8219	32831	42580217
Thrombocytopenia	77.33	20.74	135	8152	190144	42422904
Pseudomonas infection	70.71	20.74	42	8245	15881	42597167
Brain abscess	64.33	20.74	26	8261	4258	42608790
Electrocardiogram QT prolonged	63.07	20.74	61	8226	47884	42565164
Hepatic cytolysis	61.62	20.74	47	8240	26797	42586251
Vascular pseudoaneurysm thrombosis	60.28	20.74	11	8276	76	42612972
Rash maculo-papular	59.55	20.74	53	8234	37450	42575598
Candida infection	56.69	20.74	41	8246	21569	42591479
Nocardiosis	56.29	20.74	25	8262	5165	42607883
Condition aggravated	54.42	20.74	141	8146	260613	42352435
Cardiac valve vegetation	49.74	20.74	13	8274	528	42612520
Seizure	49.47	20.74	86	8201	120475	42492573
Bronchopulmonary aspergillosis	49.00	20.74	36	8251	19393	42593655
Mycobacterium fortuitum infection	43.10	20.74	11	8276	406	42612642
Toxic epidermal necrolysis	42.84	20.74	38	8249	26712	42586336
Mycobacterial peritonitis	41.34	20.74	9	8278	164	42612884
Treatment failure	40.22	20.74	55	8232	62569	42550479
Geotrichum infection	39.56	20.74	11	8276	566	42612482
Botulism	39.11	20.74	9	8278	213	42612835
Drug ineffective for unapproved indication	38.23	20.74	46	8241	46117	42566931
Proteus test positive	37.42	20.74	9	8278	259	42612789
Acute respiratory distress syndrome	37.13	20.74	37	8250	30071	42582977
Haemoperitoneum	36.13	20.74	14	8273	2052	42610996
Fatigue	36.09	20.74	20	8267	435621	42177427
Drug reaction with eosinophilia and systemic symptoms	34.96	20.74	42	8245	42033	42571015
Embolic cerebral infarction	34.87	20.74	11	8276	878	42612170
Splenic candidiasis	34.73	20.74	7	8280	86	42612962
Fungaemia	33.66	20.74	15	8272	3121	42609927
Product use in unapproved indication	33.62	20.74	95	8192	184361	42428687
Hepatic haemorrhage	33.62	20.74	10	8277	655	42612393
Intestinal ulcer	32.79	20.74	11	8276	1066	42611982
Respiratory failure	32.72	20.74	75	8212	128057	42484991
Leukocytosis	32.09	20.74	34	8253	29674	42583374
Disseminated intravascular coagulation	31.56	20.74	31	8256	24763	42588285
Wound drainage	28.69	20.74	9	8278	705	42612343
Aspergillus infection	28.39	20.74	24	8263	15813	42597235
Deafness	27.95	20.74	22	8265	13118	42599930
Pyroglutamic acidosis	27.85	20.74	9	8278	776	42612272
Pain	27.29	20.74	7	8280	244841	42368207
Graft versus host disease	26.12	20.74	21	8266	12904	42600144
Clostridium difficile colitis	25.98	20.74	26	8261	21226	42591822
Acoustic neuroma	25.91	20.74	6	8281	146	42612902
Large intestine infection	25.54	20.74	11	8276	2110	42610938
Opisthotonus	25.51	20.74	8	8279	626	42612422
Enterococcal infection	25.27	20.74	20	8267	12019	42601029
Rash morbilliform	23.94	20.74	13	8274	4140	42608908
Functional gastrointestinal disorder	23.86	20.74	11	8276	2477	42610571
Vasculitis	23.41	20.74	23	8264	18371	42594677
Pulmonary physical examination abnormal	22.40	20.74	4	8283	24	42613024
Venoocclusive disease	21.86	20.74	12	8275	3903	42609145
Anuria	21.75	20.74	18	8269	11514	42601534
Benign soft tissue neoplasm	21.62	20.74	5	8282	121	42612927
Fusarium infection	21.51	20.74	9	8278	1607	42611441
Long QT syndrome	21.33	20.74	11	8276	3156	42609892
Ecthyma	21.04	20.74	7	8280	661	42612387
Shock	20.87	20.74	27	8260	29094	42583954
Bacterial toxaemia	20.85	20.74	5	8282	142	42612906
Pancytopenia	20.79	20.74	60	8227	117683	42495365
Arthralgia	20.79	20.74	7	8280	205231	42407817

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug resistance	268.92	20.98	131	12685	56243	110520240
Multiple organ dysfunction syndrome	248.01	20.98	176	12640	151534	110424949
Pathogen resistance	219.18	20.98	81	12735	17591	110558892
Drug ineffective	217.02	20.98	514	12302	1520026	109056457
Septic shock	206.36	20.98	160	12656	157368	110419115
Ototoxicity	137.56	20.98	40	12776	4091	110572392
Eosinophilia	135.18	20.98	84	12732	57852	110518631
Thrombocytopenia	118.15	20.98	172	12644	348713	110227770
Seizure	117.07	20.98	136	12680	221049	110355434
Electrocardiogram QT prolonged	105.58	20.98	93	12723	108867	110467616
Pseudomonas infection	95.85	20.98	52	12764	27801	110548682
Geotrichum infection	94.42	20.98	23	12793	1189	110575294
Rash maculo-papular	94.03	20.98	74	12742	74148	110502335
Nocardiosis	91.64	20.98	34	12782	7452	110569031
Candida infection	85.99	20.98	59	12757	47950	110528533
Respiratory failure	84.45	20.98	114	12702	215218	110361265
Bronchopulmonary aspergillosis	79.14	20.98	47	12769	29816	110546667
Clostridium difficile colitis	76.52	20.98	53	12763	43725	110532758
Toxic epidermal necrolysis	72.79	20.98	57	12759	56670	110519813
Aspergillus infection	72.31	20.98	42	12774	25574	110550909
Hepatic cytolysis	72.12	20.98	56	12760	54997	110521486
Sepsis	69.63	20.98	131	12685	327215	110249268
Pain	68.09	20.98	14	12802	954941	109621542
Brain abscess	65.81	20.98	26	12790	6748	110569735
Vascular pseudoaneurysm thrombosis	65.46	20.98	11	12805	80	110576403
Drug reaction with eosinophilia and systemic symptoms	63.83	20.98	62	12754	82033	110494450
Renal failure	61.54	20.98	101	12715	226473	110350010
Fatigue	59.02	20.98	34	12782	1215924	109360559
Leukocytosis	58.31	20.98	49	12767	53779	110522704
Acute respiratory distress syndrome	54.70	20.98	47	12769	53151	110523332
Enterococcal infection	53.82	20.98	32	12784	20334	110556149
Product use in unapproved indication	52.23	20.98	141	12675	447236	110129247
Mycobacterium fortuitum infection	52.06	20.98	12	12804	488	110575995
Mycobacterium abscessus infection	50.14	20.98	15	12801	1691	110574792
Cardiac valve vegetation	47.98	20.98	13	12803	1027	110575456
Pancytopenia	45.90	20.98	85	12731	209528	110366955
Deafness	45.88	20.98	32	12784	26677	110549806
Drug ineffective for unapproved indication	45.78	20.98	58	12758	102780	110473703
Arthralgia	45.16	20.98	17	12799	779615	109796868
Hepatic infarction	44.03	20.98	12	12804	969	110575514
Mycobacterial peritonitis	42.94	20.98	9	12807	234	110576249
Off label use	41.55	20.98	306	12510	1499879	109076604
Disseminated intravascular coagulation	41.48	20.98	36	12780	41250	110535233
Headache	39.53	20.98	27	12789	882350	109694133
Splenic candidiasis	38.20	20.98	7	12809	88	110576395
Systemic candida	38.19	20.98	20	12796	9954	110566529
Acute kidney injury	37.31	20.98	159	12657	635271	109941212
Intestinal ulcer	37.12	20.98	13	12803	2414	110574069
Treatment failure	37.06	20.98	92	12724	277142	110299341
Klebsiella infection	36.78	20.98	25	12791	19984	110556499
Generalised tonic-clonic seizure	36.44	20.98	38	12778	54642	110521841
Botulism	35.83	20.98	9	12807	528	110575955
Acinetobacter infection	35.71	20.98	14	12802	3559	110572924
Shock	35.28	20.98	37	12779	53551	110522932
Condition aggravated	35.08	20.98	173	12643	734663	109841820
Embolic cerebral infarction	34.76	20.98	11	12805	1495	110574988
Aspergillus test positive	34.22	20.98	10	12806	1040	110575443
Hepatotoxicity	33.49	20.98	39	12777	63361	110513122
Proteus test positive	32.87	20.98	9	12807	739	110575744
Abdominal discomfort	31.97	20.98	4	12812	393854	110182629
Fall	31.96	20.98	15	12801	603467	109973016
Hepatic haemorrhage	31.85	20.98	10	12806	1324	110575159
Nephropathy toxic	31.80	20.98	26	12790	27452	110549031
Graft versus host disease	31.06	20.98	22	12794	18784	110557699
Peripheral swelling	30.71	20.98	5	12811	404029	110172454
Haemoperitoneum	30.17	20.98	14	12802	5374	110571109
Eosinophilic pneumonia acute	29.68	20.98	10	12806	1655	110574828
Staphylococcal infection	28.85	20.98	38	12778	69906	110506577
Fungaemia	28.55	20.98	14	12802	6072	110570411
Weight increased	28.13	20.98	7	12809	419637	110156846
Wound drainage	27.94	20.98	9	12807	1295	110575188
Rash morbilliform	27.78	20.98	15	12801	7936	110568547
Agranulocytosis	27.74	20.98	35	12781	61725	110514758
Heparin-induced thrombocytopenia	27.73	20.98	17	12799	11407	110565076
Abscess	27.68	20.98	24	12792	27445	110549038
Pain in extremity	27.54	20.98	11	12805	487107	110089376
Pyrexia	27.50	20.98	188	12628	898077	109678406
Drug level below therapeutic	27.39	20.98	17	12799	11656	110564827
Gamma-glutamyltransferase increased	26.36	20.98	34	12782	61275	110515208
Bone marrow failure	26.33	20.98	33	12783	57815	110518668
Hepatic failure	26.30	20.98	36	12780	68703	110507780
Neutropenia	25.32	20.98	98	12718	374522	110201961
Dermatitis exfoliative	25.30	20.98	16	12800	11331	110565152
Aplasia	25.15	20.98	14	12802	7859	110568624
Acoustic neuroma	24.59	20.98	6	12810	312	110576171
Pulmonary physical examination abnormal	24.47	20.98	4	12812	24	110576459
Hepatic lesion	24.16	20.98	14	12802	8479	110568004
HIV infection	23.91	20.98	8	12808	1295	110575188
Pyroglutamic acidosis	23.88	20.98	9	12807	2059	110574424
Nasopharyngitis	23.82	20.98	8	12808	394353	110182130
Benign soft tissue neoplasm	23.78	20.98	5	12811	132	110576351
Mucormycosis	23.73	20.98	15	12801	10613	110565870
Moraxella infection	23.63	20.98	7	12809	763	110575720
Swelling	23.24	20.98	6	12810	351035	110225448
Encephalopathy	23.15	20.98	37	12779	81018	110495465
Arthropathy	23.13	20.98	3	12813	287519	110288964
Large intestine infection	23.08	20.98	11	12805	4481	110572002
Haemodynamic instability	23.07	20.98	20	12796	22868	110553615
Hypoproteinaemia	22.98	20.98	12	12804	5933	110570550
Functional gastrointestinal disorder	22.79	20.98	12	12804	6037	110570446
Bacterial toxaemia	22.59	20.98	5	12811	169	110576314
Granulomatosis with polyangiitis	22.49	20.98	10	12806	3480	110573003
Organ failure	22.35	20.98	11	12805	4806	110571677
Toxic skin eruption	21.78	20.98	21	12795	27494	110548989
Stevens-Johnson syndrome	21.73	20.98	27	12789	46874	110529609
Synovitis	21.72	20.98	3	12813	274089	110302394
Parasitic encephalitis	21.63	20.98	4	12812	53	110576430
Leukopenia	21.59	20.98	51	12765	148740	110427743
Back pain	21.59	20.98	8	12808	370988	110205495
Stomatitis	21.31	20.98	3	12813	270239	110306244
Dizziness	21.25	20.98	30	12786	698163	109878320
Haemodialysis	21.00	20.98	17	12799	17702	110558781

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DH51	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems
ATC	J01DH56	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000900	Anti-Bacterial Agents
CHEBI has role	CHEBI:36047	antibacterial drug

Related Drugs by ATC class:

J01DH Carbapenems 10 drugs

betamipron biapenem cilastatin doripenem ertapenem meropenem panipenem relebactam tebipenem pivoxil vaborbactam

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bacterial septicemia	indication	10001005	DOID:0040085
Infection caused by Pseudomonas aeruginosa strain resistant to carbapenem antimicrobial drugs	indication	11218009
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Pneumonia due to Streptococcus	indication	34020007
Peritonitis	indication	48661000
Lower respiratory tract infection	indication	50417007
Pneumonia due to Escherichia coli	indication	51530003
Bacterial pneumonia	indication	53084003	DOID:874
Haemophilus influenzae pneumonia	indication	70036007
Infection caused by Escherichia coli strain resistant to carbapenem antimicrobial drugs	indication	71057007
Infection caused by Serratia spp resistant to carbapenem antimicrobial drugs	indication	71120004
Abdominal abscess	indication	75100008
Endometritis	indication	78623009	DOID:1002
Infection of bone	indication	111253001
Female genital tract infection	indication	125585007
Infectious disease of abdomen	indication	128070006
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Bacterial endocarditis	indication	301183007
Bacterial urinary infection	indication	312124009
Infectious disorder of joint	indication	363162000
Infection caused by Enterococcus spp resistant to carbapenem antimicrobial drugs	indication	406574007
Acute exacerbation of chronic bronchitis	indication	425748003
Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs	indication	840588006
Infection caused by Citrobacter spp resistant to carbapenem antimicrobial drugs	indication	1137353009
Gram-Negative Aerobic Bacillary Pneumonia	indication
Enterobacter Pneumonia	indication
Diabetic Foot Infection	indication
Inflammatory Disease of Female Pelvic Organs	indication
Pyrexia of unknown origin	off-label use	7520000
Inhalational anthrax	off-label use	11389007
Cutaneous anthrax	off-label use	84980006	DOID:7426
Gastrointestinal anthrax	off-label use	111798006	DOID:13386
Infection by Campylobacter fetus	off-label use	111835002
Gas gangrene caused by clostridium perfringens	off-label use	266093005
Anthrax	off-label use	409498004	DOID:7427
Melioidosis	off-label use	428111003	DOID:5052
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis	off-label use
Clostridium Perfringens Empyema	off-label use
Kidney disease	contraindication	90708001	DOID:557
Seizure disorder	contraindication	128613002
Lesion of brain	contraindication	301766008
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.9	acidic
pKa2	9.92	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	8487093	March 21, 2033	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	8487093	March 21, 2033	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI)
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	8487093	March 21, 2033	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP)

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	July 16, 2024	NEW CHEMICAL ENTITY
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	Dec. 9, 2028	NEW PATIENT POPULATION
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	July 16, 2029	GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme	PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR			CHEMBL	CHEMBL
Penicillin-binding protein 4	Enzyme	Q5D1E9_STAAU		IC50	7.30	WOMBAT-PK
Penicillin-binding protein 1	Enzyme	A1KS91_NEIMF		IC50	7	WOMBAT-PK
Beta-lactamase	Enzyme	A2RP81_CITFR		Ki	7.22	CHEMBL
Beta-lactamase GES-13	Enzyme	D1MIX9_PSEAI		IC50	6.82	CHEMBL

External reference:

ID	Source
4017969	VUID
N0000146319	NUI
D00206	KEGG_DRUG
4017969	VANDF
C0020933	UMLSCUI
CHEBI:471744	CHEBI
ID1	PDB_CHEM_ID
CHEMBL43708	ChEMBL_ID
DB01598	DRUGBANK_ID
D015378	MESH_DESCRIPTOR_UI
104838	PUBCHEM_CID
10821	IUPHAR_LIGAND_ID
71OTZ9ZE0A	UNII
5690	RXNORM
4869	MMSL
d04401	MMSL
002813	NDDF
424285002	SNOMEDCT_US
46558003	SNOMEDCT_US
74431-23-5	SECONDARY_CAS_RN
71OTZ9ZE0A	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3514	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	NDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3514	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	NDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3516	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	NDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3516	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	NDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3551	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3551	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3552	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3552	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	25 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-322	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	25 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-322	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	25 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-322	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	25 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-349	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	25 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-349	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	25 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-349	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	25 sections

Ask DrugCentral

Try a sample question

imipenem 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: